Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00095680
Status:
COMPLETED
Last Update Posted:
2010-10-22
First Post:
2004-11-05
Brief Title:
Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed Refractory Patients With Multiple Myeloma
Sponsor:
Scios Inc
Organization:
Scios Inc
Study Overview
Official Title:
A 24-week Open-label Extension Study of the Efficacy Safety and Tolerability of Oral SCIO-469 in Treatment of Relapsed Refractory Patients With Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this study is to assess the long-term effectiveness of SCIO-469 as monotherapy or in combination with bortezomib in relapsed refractory patients with multiple myeloma MM who have previously demonstrated clinical benefit in the Scios B003 study
Detailed Description:
The main objective of this study is to assess the long-term efficacy of SCIO-469 as monotherapy or in combination with bortezomib in relapsed refractory patients with multiple myeloma MM who have previously demonstrated clinical benefit in the Scios B003 study Patients took by mouth two capsules 60 mg three times a day alone or in combination with bortezomib for 168 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SCIO-469MMY2002 B006 | None | None | None |